Researchers have created a new system that uses caffeine to control gene editing and immune cell activity. The researchers designed a “Caffebody” platform that acts like a chemical switch, turning advanced treatments on and off using common substances.
In this system, cells are engineered with three components: a caffeine-sensitive nanobody called a caffebody, a partner protein, and CRISPR gene-editing tools. The system stays inactive until a person consumes a small amount of caffeine—about 20 mg, similar to a light cup of coffee or some chocolate. Caffeine causes the two proteins to bind together, which activates CRISPR or stimulates T cells to attack disease. The process can be stopped with rapamycin, a common immunosuppressant, which separates the proteins and turns the system off.
This approach could have important uses in diseases like diabetes and cancer. For example, patients might trigger insulin production by drinking coffee, or doctors could better control CAR-T cell therapy to reduce side effects. Because caffeine and rapamycin are already well understood, researchers believe this tunable and reversible system may offer a safer and more flexible way to manage gene and cell therapies.